mash tirzepatide for Retatrutide's liver data is unlike anything we've seen from a weight loss drug: • 86% liver fat reduction at 48 weeks, most of it within the first 24 weeks • 93% of Tirzepatide (Mounjaro, Zepbound), a GLP-1/GIP
Description
Semaglutide addresses core PCOS drivers by lowering insulin resistance and supporting weight loss, potentially improving hormone balance and fertility outcomes
Semaglutide shows promise for prediabetic patients seeking to prevent type 2 diabetes and lose weight simultaneously
2 day delivery.
One could argue that, given the available evidence, an agnostic wait and see position on tamoxifen DDI is ethically untenable, and that many women with breast cancer are currently being subjected to an unnecessary risk of cancer recurrence
From ending obesity to decreasing violence how far can GLP-1s go?
